Sign up to our newsletter

HyTest offers a new recombinant cardiac troponin binary complex (rec. cTn IC complex, Cat.# 8ICR3). The new complex is constructed from recombinant cTnI, and TnC isoforms. Resulting complex separated from free recombinant cTnI and TnC isoforms.

We wish you a wonderful holiday season and a happy new year 2022!

This year, we decided to donate our Christmas present funds to lonely elderly and gave a gift of companionship:

Our scientist has discovered new pairs for D-dimer immunoassay development for both chemiluminescence and lateral flow platforms.

We will be attending Medlab Middle East 2022 in the end of January.

Acute myocardial infarction (AMI) causes heart muscle damage and the release of troponin complex that can be detected in patients' blood by the measurement of its components. Cardiac troponin I (cTnI) and cardiac troponin T (cTnT).

Procalcitonin (PCT) is the main marker of disorders that are accompanied by sepsis. The PCT levels in blood are elevated during the systemic inflammation. In addition, the concentration of PCT closely correlates with the severity of inflammation, which further supports the diagnostic value of the marker. While in normal conditions the amount of non-cleaved PCT in blood is low, it increases during systemic inflammation and sepsis.

We will be attending Medica 2021 in November.

The winner of the third EFLM-HyTest Cardiac Marker award will be announced by the EFLM President during the Opening Ceremony of the 24rd IFCC-EFLM European Congress - EuroMedLab in Munich.

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (“Mindray”) (300760.SZ), a leading global provider of medical devices and solutions, has completed its previously announced acquisition of HyTest Invest Oy and its subsidiaries (“HyTest”), a global leading provider of antibodies and antigens.

The loneliness of elderly people is a problem in Finland, the homecountry of HyTest. We wanted to be a part of the solution. That is why HyTest is now collaborating with a Finnish company called Gubbe.

We will be attending the 2021 AACC Annual Meeting & Clinical Lab Expo. The exhibition will be on August 26 - 30 in Atlanta.

Serum amyloid A is the only major acute phase protein in cats. It can be used as a sensitive marker of inflammation.

HyTest's current majority owner, Summa Equity, has signed a definitive agreement to sell HyTest to Mindray, a leading global medical technology company. HyTest has been partnering with Mindray already for over ten years. In going forward, HyTest is committed to serving all of its customers and will continue to provide high-quality diagnostic raw materials as before.

Polyclonal SARS-CoV-2 NP antibodies provide an excellent addition to the mix of antibodies to select for COVID-19 Antigen test development.

Elevated levels of D-dimer have been found in the blood of patients with pulmonary embolism (PE) and deep vein thrombosis (DVT). The elevated level of D-dimer in blood is believed to be a reliable marker of pathological coagulation. During the COVID-19 pandemic D-dimer has been commonly elevated in patients with SARS-CoV-2. It has been shown to correlate with disease severity and to be a reliable prognostic marker for hospitalization and mortality assessment in patients admitted for COVID-19.

 By watching this webinar, you will learn about:
- inflammation process and its clinical importance
- the clinical value of Interleukin-6 and other inflammation markers, as well as the benefits and limitations of these markers for diagnostics
- the role of Interleukin-6 in distinguishing the severity and prognosis of COVID-19

We have now developed 7 new MAb pairs to IL-6 that are suitable for high sensitivity IL-6 assay development.

Angiotensin converting enzyme 2 (ACE2) and SARS-CoV-2 Nucleoprotein fragment N47-A173 samples available

Call for nominations! We are delighted to let you know that we are sponsoring the EFLM-HyTest Cardiac Marker Award for remarkable scientific work in the field of cardiovascular diseases.

Early diagnosis of acute myocardial infarction (AMI) as a life-threatening disorder is important for immediate evidence-based therapy. The cardiac troponin I (cTnI) is a gold standard and diagnostic cornerstone in the clinical assessment of AMI. It offers accurate and rapid AMI rule outs.